ZOLL® Heart Failure Management System* (HFMS) is a non-invasive, patch-based device that uses novel radiofrequency technology for early detection of changes in pulmonary fluid levels, an increase of which is an early indicator of heart failure decompensation. 

ZOLL HFMS also records, stores, and transmits additional patient data including heart rate, respiration rate, activity, posture, and heart rhythm (ECG) that can be used to inform care plans.

ZOLL HFMS is a non-invasive patch based device that uses novel radiofrequency technology for early detection of changes in pulmonary fluid levels, an increase in which is an early indicator of heart failure decompensation.

• Radar waves can be used to measure interstitial edema, an early sign of heart failure
• Changes in signal path delay and strength indicate changes in fluid
• Waves are highly modulated by tissue hydration, producing a very sensitive, robust measurement known as Thoracic Fluid Index (TFI)

Radiofrequency signals from the HFMS patch propagate through the lungs and are reflected back to the device. 

ZOLL HFMS is a patch with a water-resistant sensor. Patients can wear the device 24 hours a day for the prescribed duration of monitoring. Data flows back to ZOLL via the cellular- enabled gateway, allowing for monitoring of the patient’s pulmonary fluid status.

Proprietary algorithms determine patient-specific trends in data, before signs and symptoms begin, allowing for early detection of deterioration in the patient’s condition. Certified technicians from ZOLL’s Independent Diagnostic Testing Facility (IDTF) monitor and analyze the patient’s data.

ZOLL provides timely notifications to the designated physician according to predefined criteria. The data aids in the diagnosis and identification of various clinical conditions, events and/or trends, allowing for timely intervention.

ZOLL HFMS may benefit patients who: 

• Have an acute event for volume overload and have been effectively diuresed, are now stable, and will benefit from remote pulmonary fluid management to predictively prevent a recurrent hospitalization
• Have intermittent and/or poorly controlled dyspnea, orthopnea, edema, or other fluid overload-related symptoms
• Require GDMT pharmaceutical titration to control fluid overload

ZOLL HFMS may not benefit patients who: 

• Are currently experiencing symptomatic volume overload and/or are considered “wet”
• Have their fluid status being actively monitored by an implanted device
• Do not meet indications for use⁺

HFMS is ordered through the ZOLL Patient Management (ZPM) Network. For more information about ordering, click here.

ZOLL HFMS was cleared by the FDA in 2018.

ZOLL is currently accepting patients with all Medicare and most commercial insurances.

ZOLL HFMS is manufactured by ZOLL^®.

Please complete this form. A representative will respond to your shortly.

ZOLL HFMS can be prescribed for up to 90 days. 

Please complete this form to share your contact information. A representative will respond to you shortly.